Atnahs Pharma Denmark ApS: Financial statements 2025
CVR: 36699051
Source: annual report 2025, Danish Business Authority
01/04/2024 – 31/03/2025
Atnahs Pharma Denmark ApS (CVR 36699051) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 71,428,252 and a net result of DKK 47,843 compared with EUR 20,450 the year before. That is a decrease of 21.8% compared with the year before. The profit margin was 0.1%. Equity in the 2025 report amounted to DKK 2,081,649. The solvency ratio was 4.1%.
- Revenue
- DKK 71,428,252
- Gross Profit
- DKK 1,363,434
- Profit/Loss
- DKK 47,843
- Equity
- DKK 2,081,649
- Total Assets
- DKK 51,235,534
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 71.4M | 1.4M | 48K | 2.1M | 0 |
| 2024 | 91.3M EUR | 925K EUR | 20K EUR | 2M EUR | - |
| 2023 | 517.2M | -19.4M | 14.7M | 14.9M | - |
| 2022 | - | 9.8M | 3.6M | 142K | - |
| 2021 | - | 5.1M | 275K | -3.5M | - |
Official annual report
How creditworthy is Atnahs Pharma Denmark ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of November 26, 2025, CHRISTENSEN KJÆRULFF STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of Atnahs Pharma Denmark ApS.
As of November 26, 2025, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Atnahs Pharma Denmark ApS.
As of September 30, 2025, James Sang Bum Lee has left the board of directors of Atnahs Pharma Denmark ApS.
As of September 30, 2025, Zubair Javeed has left the board of directors of Atnahs Pharma Denmark ApS.
As of September 30, 2025, Neeshe Bhikhubhai Williams is registered as director of Atnahs Pharma Denmark ApS.
As of September 30, 2025, James Sang Bum Lee has stepped down as director of Atnahs Pharma Denmark ApS.
As of August 25, 2025, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Atnahs Pharma Denmark ApS.
As of August 19, 2025, KPMG P/S has stepped down as auditor of Atnahs Pharma Denmark ApS.
As of May 1, 2025, Santsagar Patel has joined the board of directors of Atnahs Pharma Denmark ApS.
As of May 1, 2025, Zubair Javeed has joined the board of directors of Atnahs Pharma Denmark ApS.
About Atnahs Pharma Denmark ApS
Atnahs Pharma Denmark ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Pharmamentum ApS. The management consists of Christoph Michael Habereder. The board consists of Mohammad Muqtadir Samy (chair), Christoph Michael Habereder and Twan Johannes Anna Nouwen. The company is owned by Atnahs Pharma UK Limited. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported revenue of EUR 52,583,756 and a net result of EUR 12,487 compared with DKK 47,843 the year before. Equity in the 2026 report amounted to EUR 2,094,136.